Â鶹Çø

Harm reduction under political pressure, projected outcomes for people who inject drugs, methadone travel barriers, medetomidine withdrawal protocols, and ketamine and stimulant treatment coverage.

Dr. Jessica Gregg, FASAM, examines the distinction between harm reduction interventions and unsheltered encampments, and argues for evidence-based policies that address root causes of homelessness.

Psilocybin use and unmet mental health treatment needs, buprenorphine in the emergency department, postpartum overdose risk with MOUD, alcohol-associated liver disease medication trends, NLP in couples therapy, and cannabis and sleep

Cannabis use disorder rising among older adults, medetomidine withdrawal driving ICU admissions, opioid settlement fund oversight gaps, gambling comorbidity in SUD treatment, and the polygenic architecture of tobacco use disorder.

Cannabis use disorder rising in California adolescents post-legalization, cannabinoid hyperemesis syndrome review, ADHD and elevated SUD risk, buprenorphine access and child welfare outcomes, and GLP-1 agonists for alcohol use disorder.

Buprenorphine discontinuation challenges with 1 in 3 prescriptions abandoned, fentanyl-stimulant co-use risks, opioid-sedative co-use patterns, oral nicotine pouch trends in adolescents, and FDA hearing on psychedelics.

Stimulant-only overdose deaths rising amid opioid decline, care navigation for methamphetamine use disorder, cannabis detected in 21% of overdose deaths, prescription cannabis use disorder, adolescent polysubstance co-use and dosing, Addiction Consult Services reducing readmissions, prenatal alcohol exposure and brain maturation, and youth substance use ED visits.

Fatal overdose isolation patterns from SUDORS 2022–2024, police drug market disruptions and overdose risk in San Francisco, medetomidine emergence in Philadelphia, methadone versus buprenorphine survival after nonfatal overdose, expanding alcohol screening to reduce premature mortality, unauthorized e-cigarette market dominance, and ADAPT for adolescent SUD treatment.

E-cigarette cessation recommendations for US clinicians, early buprenorphine initiation and hospital discharge outcomes, vending machine naloxone access post-incarceration, global OUD treatment and harm reduction survey, nonmedical gabapentin use patterns, and Meta's $18 billion social media addiction settlement.

Guest editorial on healing and connection in addiction medicine, plus semaglutide for AUD, HRV biosignatures for craving, THC and airway dysfunction, self-management programs for SUD, and nicotine vaping trends.